IL6 and obesity disorder: When released by adipose tissue as adipokines, tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) promote low-grade systemic inflammation, which in turn is associated with chronic deleterious conditions such as insulin resistance, T2DM and obesity [2–5].